Frank Sierawski is a 10+ year late-stage lung cancer survivor who has been the beneficiary of biomarker testing and breakthrough technologies. Continued use of a targeted therapy has kept him with no evidence of disease since 2017. Frank has held leadership positions in Finance, Audit, and Strategic Planning at Union Pacific Railroad. (more ...) Frank attends the annual LUNGevity Scientific and Clinical Roundtable to represent the patient voice. Frank actively advocates for LUNGevity and the ALK+ lung cancer community and calls on industry, regulators, and fellow patients to challenge the status quo and explore what’s possible. He received a BSBA in Accounting from Creighton University and an MBA from the University of Nebraska at Omaha.
